Improving the use of research evidence in guideline development: Introduction

被引：93

作者：

Oxman A.D. ^{[1
]}

Fretheim A. ^{[1
]}

Schünemann H.J. ^{[2
]}

Haines A. ^{[3
]}

Langer A. ^{[3
]}

Pang T. ^{[3
]}

Panisset U. ^{[3
]}

Whitworth J. ^{[3
]}

机构：

[1] Norwegian Knowledge Centre for the Health Services, N-0130 Oslo

[2] INFORMA, S.C. Epidemiologia, Istituto Regina Elena, 00144 Rome

[3] Subcommittee on the Use of Research Evidence (SURE), WHO

来源：

Health Research Policy and Systems | / 4卷 / 1期

关键词：

World Health Organisation; Research Evidence; Guideline Development; International Expert; Public Health Agency;

D O I：

10.1186/1478-4505-4-12

中图分类号：

学科分类号：

摘要：

In 2005 the World Health Organisation (WHO) asked its Advisory Committee on Health Research (ACHR) for advice on ways in which WHO can improve the use of research evidence in the development of recommendations, including guidelines and policies. The ACHR established the Subcommittee on the Use of Research Evidence (SURE) to collect background documentation and consult widely among WHO staff, international experts and end users of WHO recommendations to inform its advice to WHO. We have prepared a series of reviews of methods that are used in the development of guidelines as part of this background documentation. We describe here the background and methods of these reviews, which are being published in Health Research Policy and Systems together with this introduction. © 2006 Oxman et al; licensee BioMed Central Ltd.

引用

共 31 条

[1] Oxman A.D., Guyatt G.H., The science of reviewing research, Annals of the New York Academy of Science, 703, pp. 125-134, (1993)
[2] Antman E.M., Lau J., Kupelnick B., Mosteller F., Chalmers T.C., A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction, JAMA, 268, pp. 240-248, (1992)
[3] Silagy C.A., Stead L.F., Lancaster T., Use of systematic reviews in clinical practice guidelines: Case study of smoking cessation, BMJ, 323, pp. 833-836, (2001)
[4] Vigna-Taglianti F., Vineis P., Liberati A., Faggiano F., Quality of systematic reviews used in guidelines for oncology practice, Annals of Oncology, 17, pp. 691-701, (2006)
[5] Bradbury J., Storm over WHO-ISH hypertension guidelines, Lancet, 353, (1999)
[6] Horton R., WHO: The casualties and compromises of renewal, Lancet, 359, pp. 1605-1611, (2002)
[7] Laing R., Waning B., Gray A., Ford N., Hoen E., 25 years of the WHO essential medicines lists: Progress and challenges, Lancet, 36, pp. 1723-1729, (2003)
[8] McCarthy M., Critics slam draft WHO report on homoeopathy, Lancet, 366, (2005)
[9] Oxman A.D., Lavis J.N., Fretheim A., The use of evidence in WHO recommendations, Lancet
[10] Shaneyfelt T.M., Mayo-Smith M.F., Rothwangl J., Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature, JAMA, 281, pp. 1900-1905, (1999)

← 1 2 3 4 →